Physician survey of 84 endocrinologists and primary care physicians on their impressions and expected use of Amylin's and Alkermes's Bydureon (once-weekly exenatide)
On January 27, 2012, the FDA approved Amylin's and Alkermes's Bydureon (once-weekly exenatide) for adults with type 2 diabetes. This survey shows broad enthusiasm for the drug among endocrinologists and PCPs, but initial excitement may wane as physicians fully weigh such factors as comparative efficacy with Novo Nordisk's Victoza (liraglutide), injection device size and convenience, and cost.
FEATURES AND BENEFITS
- Physicians were asked to assess their impressions of Bydureon in terms of efficacy, safety, tolerability, expected use, and other important factors
- Key questions are broken down by specialty or familiarity to highlight difference in physician perceptions
- Datamonitor anticipates that the initial enthusiasm will ultimately be muted once physicians gain experience with the drug. Nevertheless, a once-weekly antidiabetic agent clearly represents an attractive option for type 2 diabetes patients, and physicians expect the drug to be a welcome addition to their armamentarium.
YOUR KEY QUESTIONS ANSWERED
- Assess physicians' opinions of Bydureon as compared with Amylin's twice-daily Byetta (exenatide) and Novo Nordisk's once-daily Victoza (liraglutide)
- Determine physicians' expectations for Bydureon's uptake, line of therapy, and use in combination with other antidiabetics
- Evaluate how Bydureon may expand the overall market for GLP-1 agonists